Praneeth Kumar Reddy Bandaru

Dr. Praneeth Kumar Reddy Bandaru

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in International Journal of Hepatology
Verified
Journal Article
Open access
PDF file
AFArnold Nongmoh Forlemu
Arnold Nongmoh Forlemu
RMRaissa Nana Sede Mbakop
Raissa Nana Sede Mbakop
PBPraneeth Kumar Reddy Bandaru
Praneeth Kumar Reddy Bandaru
VGVijay Gayam
Vijay Gayam
HMHamsika Moparty
Hamsika Moparty
MOMarco Olivera
Marco Olivera
Background. Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality. Findings of microvascular invasion (MVI) in patients with HCC have emerged as an important prognostic factor for poor survival after tumor resection. Aim. This study evaluated the relation between MVI and HCC within various anatomical Couinaud’s segments of the liver. Method. A multicenter retrospective review of HCC records was conducted from 2012 to 2017. HCC cases were identified using ICD-9 and 10 codes 155, C22.0, and C22.8. HCC patients who underwent liver transplants were included in this study. Liver segment of the location of HCC was obtained from radiographic records, and MVI information was obtained from pathology reports. Segmental distributions of HCC in MVI versus non-MVI groups were compared using Wilcoxon rank sum tests. value was set at <0.05. Results. We analyzed 120 HCC patients who underwent liver transplantation. The mean age of our cohort was 57 years, and the most common etiology of liver disease was hepatitis C at 58.3%. The median HCC size was 3.1 cm, and MVI was present in 23.3% of the explanted specimens. MVI was 2 to 3 times significantly higher in patients with HCC affecting segments 2 and 3 and segments 4b and 5 ( ). Moreover, median survival was significantly lower in patients with MVI versus those without MVI (50 vs. 137 months, ). Conclusion. MVI was significantly higher in HCC tumors located in liver segments 2 and 3 and 4b and 5, and survival was lower in patients with MVI compared with those without.

25 September 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
MGManasa Ginjupalli
Manasa Ginjupalli
JJJayalekshmi Jayakumar
Jayalekshmi Jayakumar
AFArnold Forlemu
Arnold Forlemu
ASAnuj Raj Sharma
Anuj Raj Sharma
PBPraneeth Kumar Reddy Bandaru
Praneeth Kumar Reddy Bandaru
MRMadhavi Reddy
Madhavi Reddy
Background: Non-islet cell tumor hypoglycemia is increasingly reported with gastrointestinal stromal tumors (GIST), but population-level estimates of its clinical impact are limited. We evaluated associations between hypoglycemia and inpatient outcomes among GIST hospitalizations. Methods: We conducted a retrospective cross-sectional study of the National Inpatient Sample (NIS) 2018–2020. Adult GIST discharges were identified by ICD-10-CM codes and stratified by hypoglycemia. Primary outcomes were in-hospital mortality and resource utilization—length of stay (LOS) and total hospital charge. Secondary outcomes included malnutrition, sepsis, ascites, peritonitis, bowel perforation, intestinal obstruction, gastrointestinal bleeding, and iron deficiency anemia. Analyses used survey-weighted logistic regression for binary outcomes and generalized linear models for continuous outcomes. A propensity score-matched sensitivity analysis balanced sepsis and malnutrition. Results: Among 61,725 GIST hospitalizations, 0.72% had hypoglycemia. Mortality was 12.6% with hypoglycemia vs. 3.1% without; adjusted odds of death were higher (aOR 4.16, 95% CI 2.06–8.37; p < 0.001). Hypoglycemia was also associated with malnutrition (aOR 5.63, 3.37–9.40), sepsis (aOR 4.00, 2.24–7.14), ascites (aOR 3.43, 1.63–7.19), and peritonitis (aOR 2.91, 1.17–7.22). LOS was 4.61 days longer on average (not significant; p = 0.185), and total hospital charge was $5218 higher (β = 19,116.8; p = 0.95). In the matched cohort, the mortality association attenuated but persisted (aOR 1.38, 1.27–1.49; p < 0.001); peritonitis remained significant (aOR 1.10, 1.04–1.17), intestinal obstruction (aOR 4.91, 3.44–7.05) and iron deficiency anemia (aOR 3.54, 1.62–7.74) became significant, while ascites and gastrointestinal bleeding were not significant. Conclusions: Hypoglycemia in GIST, although uncommon, marks a higher-risk inpatient trajectory with increased mortality and several complications; these signals largely persist after balancing severity proxies. Resource-use differences were directionally higher but not statistically significant. Recognition of hypoglycemia may aid risk stratification and inpatient management in GIST.

28 August 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
MGManasa Ginjupalli
Manasa Ginjupalli
PBPraneeth Kumar Reddy Bandaru
Praneeth Kumar Reddy Bandaru
ASAnuj Raj Sharma
Anuj Raj Sharma
JJJayalekshmi Jayakumar
Jayalekshmi Jayakumar
RFRaissa Nana Sede Mbakop Forlemu
Raissa Nana Sede Mbakop Forlemu
MRMadhavi Reddy
Madhavi Reddy
Background: Hepatocellular carcinoma (HCC) is a major global health burden and a leading cause of cancer-related deaths. While aspirin has shown potential chemopreventive effects in chronic liver disease, its impact on clinical outcomes among patients hospitalized with HCC remains under-investigated. Methods: Using the National Inpatient Sample (NIS) from 2016 to 2022, we conducted a retrospective cohort study to evaluate the association between aspirin use and clinical outcomes in adult HCC hospitalizations. Patients were stratified based on documented aspirin use, and propensity score matching with inverse probability of treatment weighting (IPTW) was applied to minimize confounding. The primary outcome was in-hospital mortality; secondary outcomes included morbidity-related complications, hospital length of stay, and total charges. Results: Among 337,730 hospitalizations with HCC, 8.37% involved aspirin use. Aspirin users demonstrated significantly lower in-hospital mortality (5.2% vs. 10.09%), with an adjusted odds ratio (OR) of 0.58 (95% CI: 0.50–0.68; p < 0.001). Aspirin use was also associated with shorter hospital stays (5.42 vs. 6.39 days), lower total charges ($80,310 vs. $95,098), and reduced incidence of complications, including acute liver failure, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, sepsis, ICU admission, and acute kidney injury. Importantly, no statistically significant increase in gastrointestinal or variceal bleeding was observed among aspirin users. Conclusions: These findings suggest that aspirin use may reduce mortality, morbidity, and healthcare burden in patients hospitalized with HCC.


6 July 2023 in Gastroenterology
Verified
Journal Article
Closed access
AFArnold N. Forlemu
Arnold N. Forlemu
PBPraneeth Kumar Reddy Bandaru
Praneeth Kumar Reddy Bandaru
VGVijay Gayam
Vijay Gayam
RMRaissa Nana Sede Mbakop
Raissa Nana Sede Mbakop
JSJamil Shah
Jamil Shah
DEDenzil Etienne
Denzil Etienne